Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study
Background: Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 c...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224003989 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846099099714060288 |
|---|---|
| author | Tanguy Dequidt Quentin Richier Céline Louapre Florence Ader Yanis Merad Nicolas Lauwerier Christine Jacomet Michel Carles Charlotte Biron Vincent Gendrin Clément Marlat François Danion Tristan M Lepage Albert Sotto Loïc Bourdellon Alexandre Mania Martin Martinot Georges Le Falher Alexis Ferre Benoit Pilmis Guillaume Gondran Pierre Simeone Matthieu Henry Toufik Kamel Simon Ray Sophie Ancellin Nicolas Mélé Fabrice Camou Marjolaine Destremau Jeremy Sellenet Noémie Zucman Marion Le Maréchal Khawla Mellouki Marie-Elodie Langlois David Luque Paz Maud Mousset Catherine Leclerc Agnès Sommet Karine Lacombe Guillaume Martin-Blondel |
| author_facet | Tanguy Dequidt Quentin Richier Céline Louapre Florence Ader Yanis Merad Nicolas Lauwerier Christine Jacomet Michel Carles Charlotte Biron Vincent Gendrin Clément Marlat François Danion Tristan M Lepage Albert Sotto Loïc Bourdellon Alexandre Mania Martin Martinot Georges Le Falher Alexis Ferre Benoit Pilmis Guillaume Gondran Pierre Simeone Matthieu Henry Toufik Kamel Simon Ray Sophie Ancellin Nicolas Mélé Fabrice Camou Marjolaine Destremau Jeremy Sellenet Noémie Zucman Marion Le Maréchal Khawla Mellouki Marie-Elodie Langlois David Luque Paz Maud Mousset Catherine Leclerc Agnès Sommet Karine Lacombe Guillaume Martin-Blondel |
| author_sort | Tanguy Dequidt |
| collection | DOAJ |
| description | Background: Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 convalescent plasma (CCP) in patients with MS or NMOSD exposed to anti-CD20 and infected by SARS-CoV-2. Methods: This French national, retrospective cohort study was conducted between November 2020 and June 2023. Patients with MS or NMOSD, under anti-CD20 mAbs, with symptomatic COVID-19 and treated by CCP were screened. Protracted COVID-19 was defined by a duration of symptoms >21 days. The primary endpoint was the overall survival 30 days after CCP administration. Results: Ninety-two patients from 34 hospitals were included, 84 (91%) with MS and 8 (9%) with NMOSD. Overall, 30-day survival was 97% (IC95%: 91-99). SARS-CoV-2 viremia was positive in 47/75 (61%) patients before CCP versus 9/59 (15%) seven days post-CCP. In the 52 patients (57%) with protracted COVID-19, the duration of symptoms before CCP was 51 [28-69] days, including fever in 75% of cases, which disappeared in 100% of patients 7 days post-CCP. Conclusions: CCP could be a therapeutic option in patients exposed to anti-CD20 mAbs for inflammatory demyelinating disease, particularly in those with protracted COVID-19. |
| format | Article |
| id | doaj-art-911f9c414d384f3093fa2e1b47fe44c2 |
| institution | Kabale University |
| issn | 1201-9712 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj-art-911f9c414d384f3093fa2e1b47fe44c22025-01-01T05:09:53ZengElsevierInternational Journal of Infectious Diseases1201-97122025-02-01151107323Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective studyTanguy Dequidt0Quentin Richier1Céline Louapre2Florence Ader3Yanis Merad4Nicolas Lauwerier5Christine Jacomet6Michel Carles7Charlotte Biron8Vincent Gendrin9Clément Marlat10François Danion11Tristan M Lepage12Albert Sotto13Loïc Bourdellon14Alexandre Mania15Martin Martinot16Georges Le Falher17Alexis Ferre18Benoit Pilmis19Guillaume Gondran20Pierre Simeone21Matthieu Henry22Toufik Kamel23Simon Ray24Sophie Ancellin25Nicolas Mélé26Fabrice Camou27Marjolaine Destremau28Jeremy Sellenet29Noémie Zucman30Marion Le Maréchal31Khawla Mellouki32Marie-Elodie Langlois33David Luque Paz34Maud Mousset35Catherine Leclerc36Agnès Sommet37Karine Lacombe38Guillaume Martin-Blondel39Department of Infectious Diseases, Guadeloupe University hospital, Pointe-à-Pitre, France; Corresponding author.Sorbonne University, Department of Infectious Diseases, Saint Antoine Hospital, APHP, Paris, FranceSorbonne University, Department of Neurology, Pitié Salpêtrière Hospital, APHP, CIC neurosciences, Paris Brain Institute, Paris, FranceDepartment of Infectious Diseases, Hospices Civils de Lyon, Lyon, FranceDepartment of Infectious Diseases, Hospices Civils de Lyon, Lyon, FranceDepartment of Infectious Diseases, Lille University Hospital, Lille, FranceDepartment of Infectious Diseases, Clermont-Ferrand University Hospital, Clermont-Ferrand, FranceDepartment of Infectious Diseases, Nice University Hospital, Nice, FranceDepartment of Infectious Diseases, Nantes University Hospital, Nantes, FranceDepartment of Infectious Diseases, Nord Franche-Comté Hospital, Belfort, FranceDepartment of Infectious Diseases, Rouen University Hospital, Rouen, FranceDepartment of Infectious Diseases, Strasbourg University Hospital, Strasbourg, FranceDepartment of Infectious Diseases, Montpellier University Hospital, Montpellier, FranceDepartment of Infectious Diseases, Nimes University Hospital, Nimes, FranceMedicine A unit, Emile Durkheim Hospital, Epinal, FranceDepartment of Internal Medicine, Henri Mondor Hospital, Aurillac, FranceDepartment of Infectious Diseases, Colmar Hospital, Colmar, FranceDepartment of Internal Medicine, Béziers Hospital, Béziers, FranceIntensive Care Unit, Versailles Hospital, Le Chesnay, FranceAntimicrobial Stewardship Team, Microbiology Unit, Groupe Hospitalier Paris Saint Joseph, Paris, FranceDepartment of Internal Medicine, Limoges University Hospital, Limoges, FranceDepartment of Anesthesiology and Critical Care Medicine, University Hospital Timone, APHM, Marseille, FranceMedical-Surgical Intensive Care Unit, District Hospital Center, La Roche sur Yon, FranceIntensive Care Unit, Orléans University Hospital, Orléans, FranceDepartment of Infectious Diseases, Rodez Hospital, Rodez, FranceDepartment of Infectious Diseases, Auch Hospital, Auch, FranceDepartment of Neurology, GHU Paris Psychiatrie et Neurosciences, Sainte-Anne Hospital, Paris, FranceIntensive Care and Infectious Disease Unit, Groupe Saint-André, Bordeaux University Hospital, Bordeaux, FranceIntensive Care and Infectious Disease Unit, Groupe Saint-André, Bordeaux University Hospital, Bordeaux, FranceDepartment of Internal Medicine, Saint Jean Sud de France Clinic, Saint-Jean-de-Vedas, FranceIntensive Care Unit, CH Annecy Genevois, Epagny Metz-Tessy, FranceUniv. Grenoble Alpes, Infectious Diseases Department, CHU Grenoble Alpes, Grenoble, FranceDepartment of Infectious Diseases, Claude Bernard University Lyon 1, Valence Hospital Center, Valence, FranceDepartment of Internal Medicine and Infectious Diseases, Saint Joseph Saint Luc Hospital, Lyon, FranceInfectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, FranceIntensive Care Unit, Comminges Pyrénées Hospital, Saint-Gaudens, FranceDepartment of Infectious Diseases, CHI Poissy - Saint-Germain-en-Laye, Saint-Germain-en-Laye, FranceClinical Investigation Center, Toulouse University Hospital, Toulouse, FranceSorbonne University, IPLESP Inserm, Infectious Diseases Department, Saint Antoine Hospital, APHP, Paris, FranceDepartment of Infectious Diseases, Toulouse University Hospital, Toulouse, France; Toulouse Institute for Infectious and Inflammatory Diseases, INSERM UMR1291 - CNRS UMR5051 - Toulouse III University, Toulouse, FranceBackground: Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 convalescent plasma (CCP) in patients with MS or NMOSD exposed to anti-CD20 and infected by SARS-CoV-2. Methods: This French national, retrospective cohort study was conducted between November 2020 and June 2023. Patients with MS or NMOSD, under anti-CD20 mAbs, with symptomatic COVID-19 and treated by CCP were screened. Protracted COVID-19 was defined by a duration of symptoms >21 days. The primary endpoint was the overall survival 30 days after CCP administration. Results: Ninety-two patients from 34 hospitals were included, 84 (91%) with MS and 8 (9%) with NMOSD. Overall, 30-day survival was 97% (IC95%: 91-99). SARS-CoV-2 viremia was positive in 47/75 (61%) patients before CCP versus 9/59 (15%) seven days post-CCP. In the 52 patients (57%) with protracted COVID-19, the duration of symptoms before CCP was 51 [28-69] days, including fever in 75% of cases, which disappeared in 100% of patients 7 days post-CCP. Conclusions: CCP could be a therapeutic option in patients exposed to anti-CD20 mAbs for inflammatory demyelinating disease, particularly in those with protracted COVID-19.http://www.sciencedirect.com/science/article/pii/S1201971224003989SARS-CoV-2Protracted COVID-19Convalescent plasmaAnti-CD20 antibodiesMultiple sclerosisNeuromyelitis optica |
| spellingShingle | Tanguy Dequidt Quentin Richier Céline Louapre Florence Ader Yanis Merad Nicolas Lauwerier Christine Jacomet Michel Carles Charlotte Biron Vincent Gendrin Clément Marlat François Danion Tristan M Lepage Albert Sotto Loïc Bourdellon Alexandre Mania Martin Martinot Georges Le Falher Alexis Ferre Benoit Pilmis Guillaume Gondran Pierre Simeone Matthieu Henry Toufik Kamel Simon Ray Sophie Ancellin Nicolas Mélé Fabrice Camou Marjolaine Destremau Jeremy Sellenet Noémie Zucman Marion Le Maréchal Khawla Mellouki Marie-Elodie Langlois David Luque Paz Maud Mousset Catherine Leclerc Agnès Sommet Karine Lacombe Guillaume Martin-Blondel Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study International Journal of Infectious Diseases SARS-CoV-2 Protracted COVID-19 Convalescent plasma Anti-CD20 antibodies Multiple sclerosis Neuromyelitis optica |
| title | Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study |
| title_full | Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study |
| title_fullStr | Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study |
| title_full_unstemmed | Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study |
| title_short | Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study |
| title_sort | convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis optica spectrum disorder with covid 19 a multicenter retrospective study |
| topic | SARS-CoV-2 Protracted COVID-19 Convalescent plasma Anti-CD20 antibodies Multiple sclerosis Neuromyelitis optica |
| url | http://www.sciencedirect.com/science/article/pii/S1201971224003989 |
| work_keys_str_mv | AT tanguydequidt convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT quentinrichier convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT celinelouapre convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT florenceader convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT yanismerad convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT nicolaslauwerier convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT christinejacomet convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT michelcarles convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT charlottebiron convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT vincentgendrin convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT clementmarlat convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT francoisdanion convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT tristanmlepage convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT albertsotto convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT loicbourdellon convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT alexandremania convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT martinmartinot convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT georgeslefalher convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT alexisferre convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT benoitpilmis convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT guillaumegondran convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT pierresimeone convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT matthieuhenry convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT toufikkamel convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT simonray convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT sophieancellin convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT nicolasmele convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT fabricecamou convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT marjolainedestremau convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT jeremysellenet convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT noemiezucman convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT marionlemarechal convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT khawlamellouki convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT marieelodielanglois convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT davidluquepaz convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT maudmousset convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT catherineleclerc convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT agnessommet convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT karinelacombe convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy AT guillaumemartinblondel convalescentplasmainpatientsreceivingrituximaborocrelizumabformultiplesclerosisorneuromyelitisopticaspectrumdisorderwithcovid19amulticenterretrospectivestudy |